Thrivent Financial for Lutherans Reduces Position in Certara, Inc. (NASDAQ:CERT)

Thrivent Financial for Lutherans cut its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 44.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 89,459 shares of the company's stock after selling 70,954 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.06% of Certara worth $1,239,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Blue Trust Inc. bought a new stake in Certara during the 2nd quarter valued at approximately $26,000. Pineridge Advisors LLC purchased a new position in shares of Certara in the fourth quarter worth $28,000. Innealta Capital LLC bought a new position in shares of Certara during the second quarter worth $36,000. YHB Investment Advisors Inc. purchased a new position in Certara during the first quarter valued at $47,000. Finally, Intech Investment Management LLC bought a new stake in Certara in the 2nd quarter valued at $152,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CERT has been the topic of several research reports. Barclays reduced their price target on shares of Certara from $18.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday, June 28th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Wednesday, July 10th. KeyCorp cut their target price on Certara from $23.00 to $20.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Robert W. Baird reduced their target price on shares of Certara from $19.00 to $18.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 7th. Finally, UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Certara presently has a consensus rating of "Hold" and an average price target of $17.79.

Certara Stock Up 0.9 %

Shares of CERT stock traded up $0.10 on Friday, hitting $11.09. The stock had a trading volume of 916,513 shares, compared to its average volume of 738,071. Certara, Inc. has a one year low of $10.35 and a one year high of $19.87. The business has a 50 day moving average price of $12.28 and a 200 day moving average price of $14.85. The company has a market cap of $1.78 billion, a PE ratio of -28.44, a P/E/G ratio of 5.17 and a beta of 1.49. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million for the quarter, compared to analysts' expectations of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company's revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. Research analysts anticipate that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.39% of the stock is currently owned by company insiders.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.